Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
Public ClinicalTrials.gov record NCT03163368. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors
Study identification
- NCT ID
- NCT03163368
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 25 participants
Conditions and interventions
Conditions
Interventions
- Neoadjuvant stereotactic radiosurgery Radiation
- Neurosurgical resection Procedure
Radiation · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 8, 2017
- Primary completion
- Dec 14, 2022
- Completion
- May 31, 2026
- Last update posted
- Apr 16, 2026
2017 – 2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Brain Metastases trials
Other public records listing Brain Metastases. Sorted by last update posted; newest first. Not a recommendation.
- NCT04073966: MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets Recruiting
- NCT02886585: Pembrolizumab In Central Nervous System Metastases Active, not recruiting
- NCT03726359: Phase I Study of Fractionated Stereotactic Radiation Therapy Active, not recruiting
- NCT03223922: Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases Active, not recruiting
- NCT05419076: A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain Recruiting
- NCT06015295: A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03163368, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03163368 live on ClinicalTrials.gov.